Neoadjuvant or adjuvant therapy for resectable or borderline resectable pancreatic cancer: Which is preferred? Editorial

   


Authors: O'Reilly, E. M.; Ferrone, C.
Title: Neoadjuvant or adjuvant therapy for resectable or borderline resectable pancreatic cancer: Which is preferred?
Journal Title: Journal of Clinical Oncology
Volume: 38
Issue: 16
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2020-06-01
Start Page: 1757
End Page: 1759
Language: English
DOI: 10.1200/jco.19.03318
PUBMED: 32119598
PROVIDER: scopus
PMCID: PMC7255981
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085630342&doi=10.1200%2fJCO.19.03318&partnerID=40&md5=18eccebebed9aae3483c5f3232a56a07
Notes: Editorial -- Export Date: 1 July 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Eileen O'Reilly
    780 O'Reilly
Related MSK Work